Efficacy of Rituximab as Adjunctive Therapy to Immunosuppressive Agents in Adult Primary Focal Segmental Glomerulosclerosis.

ABSTRACT:

Introduction

Primary focal segmental glomerulosclerosis (FSGS) is a rare, likely immune-related disease. Rituximab (RTX) may help manage it, but existing adult data are limited and mainly based on case reports or case series. We aimed to evaluate RTX treatment outcomes in a large, multicenter adult cohort.

Methods

This was a retrospective study of 160 patients with primary FSGS treated with RTX as adjunctive therapy to standard immunosuppressive agents between March 2015 and June 2023, that evaluated treatment responses at 3, 6, and 12 months, followed by an extended 24-month follow-up to assess long-term outcomes. Treatment outcomes included complete response (CR), partial response (PR), or no response. Treatment-related adverse effects and relapse-free survival (RFS) were

SUBMITTER: Mohamed ON 

PROVIDER: S-EPMC12640038 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature